For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 10,960 | |||
| General and administrative | 11,328 | |||
| Long-lived asset impairment | 0 | |||
| Total operating expenses | 22,288 | |||
| Loss from operations | -22,288 | |||
| Interest income | 1,239 | |||
| Interest expense | 32 | |||
| Other expense, net | -4 | |||
| Net loss | -21,085 | |||
| Net loss attributable to common stockholders | -21,085 | |||
| Basic EPS | -16.72 | |||
| Diluted EPS | -16.72 | |||
| Basic Average Shares | 1,260,772 | |||
| Diluted Average Shares | 1,260,772 | |||
Sensei Biotherapeutics, Inc. (SNSE)
Sensei Biotherapeutics, Inc. (SNSE)